Terms ending in 2034

The Institut Pasteur

Every in-force patent on The Institut Pasteur's record whose computed term ends in 2034, whoever holds it now. Soonest term end first, then patent number.

Patent	Title	Holder	Status	Expires	Confidence
US 9,889,193	Use of a Genetically Modified Infectious Measles Virus with Enhanced Pro-Apoptotic Properties (Mv-Deltac Virus) in Cancer Therapy Nantes Universite In force Term ends Jan 20, 2034 · High confidence	Nantes Universite	In force	Term ends Jan 20, 2034	High confidence
US 10,314,905	Use of a Genetically Modified Infectious Measles Virus with Enhanced Pro-Apoptotic Properties (Mv-Deltac Virus) in Cancer Therapy Nantes Universite In force Term ends Jan 20, 2034 · High confidence	Nantes Universite	In force	Term ends Jan 20, 2034	High confidence
US 10,980,873	Use of a Genetically Modified Infectious Measles Virus with Enhanced Pro-Apoptotic Properties (Mv-Deltac Virus) in Cancer Therapy Nantes Universite In force Term ends Jan 20, 2034 · High confidence	Nantes Universite	In force	Term ends Jan 20, 2034	High confidence
US 11,504,049	Olfactory Means Useful in the Diagnosis and Treatment of Mood Depression Centre National de la Recherche Scientifique In force Term ends Apr 10, 2034 · Medium confidence	Centre National de la Recherche Scientifique	In force	Term ends Apr 10, 2034	Medium confidence
US 12,478,652	Bacteriophage Therapy Institut Pasteur In force Term ends Apr 30, 2034 · Low confidence	Institut Pasteur	In force	Term ends Apr 30, 2034	Low confidence
US 9,547,006	Correlation of Disease Activity with Clonal Expansions of Human Papillomavirus 16-Specific CD8+ T-Cells in Patients with Severe Erosive Oral Lichen Planus Université Paris Cité In force Term ends Aug 8, 2034 · High confidence	Université Paris Cité	In force	Term ends Aug 8, 2034	High confidence
US 10,018,629	Correlation of Disease Activity with Clonal Expansions of Human Papillomavirus 16-Specific CD8+ T-Cells in Patients with Severe Erosive Oral Lichen Planus Université Paris Cité In force Term ends Aug 8, 2034 · High confidence	Université Paris Cité	In force	Term ends Aug 8, 2034	High confidence
US 10,300,128	Subunit Vaccine Platform Based on Multimeric Ribonucleoproteins Comprising Nucleoproteins of a Non-Segmented Negative-Strand RNA Virus as Carriers of Heterologous Polypeptides Université Paris Cité In force Term ends Oct 8, 2034 · High confidence	Université Paris Cité	In force	Term ends Oct 8, 2034	High confidence
US D863,591	Cell Sample Box Transport Holder Institut Pasteur In force Term ends Oct 15, 2034 · High confidence	Institut Pasteur	In force	Term ends Oct 15, 2034	High confidence
US 9,738,712	Camelid Single-Domain Antibody Directed Against Amyloid Beta and Methods for Producing Conjugates Thereof F. Hoffman-la Roche AG, Institut Pasteur, Centre National de la Recherche Scientifique (CNRS) and Commissariat a l'Energie Atomique et aux Energies Alternatives In force Term ends Nov 13, 2034 · High confidence	F. Hoffman-la Roche AG, Institut Pasteur, Centre National de la Recherche Scientifique (CNRS) and Commissariat a l'Energie Atomique et aux Energies Alternatives	In force	Term ends Nov 13, 2034	High confidence
3 more term ends in 2034 · Pro

10 of 13 patents shown. Soonest term end first, then patent number.

Pro members see all 13.

Upgrade to Pro

7 of these are in force and held by The Institut Pasteur.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.